The present study focused on understanding the prognostic value of the methylenetetrahydrofolate reductase (MTHFR) single nucleotide polymorphisms rs1801133 (C667T) and rs1801131 (A1298C) in patients with colorectal cancer (CRC).
of rs1801133 and rs1801131 showed that patients with CRC from Asian regions and Western regions demonstrated similar results.
Conclusions:
The MTHFR rs1801133 polymorphism was not associated with the prognosis of patients with CRC; however, rs1801131 may be associated with the prognosis of patients with CRC. Well-designed prospective studies are necessary to obtain a better understanding of the prognostic value of rs1801133 and rs1801131. KEYWORDS colorectal cancer, gene polymorphism, meta-analysis, methylenetetrahydrofolate reductase,
As the third most commonly diagnosed cancer, colorectal cancer (CRC) has a worldwide incidence of over 1.3 million and a mortality rate of approximately 50%. [1] [2] [3] Although the incidence of CRC has decreased in recent years because of improvements in its early diagnosis and treatment, 1 the number of CRC cases continues to increase worldwide. Despite recent advances in treatment modalities, the 5-year survival rate of patients with advanced CRC is not satisfactory as a result of recurrence and drug resistance. 4 Methylenetetrahydrofolate reductase (MTHFR) is required for folate metabolism, intracellular homeostasis and DNA synthesis. It converts 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5methyltetrahydrofolate (5-MTHF), which is the major circulating form of folate in the blood and provides methyl groups to convert homocysteine into methionine. MTHFR contributes to the imbalance in methylation reactions, leading to genomic DNA hypomethylation, and influences folate metabolism. 5, 6 The two most common loci for MTHFR single nucleotide polymorphisms (SNPs) are rs1801133 (C677T) and rs1801131 (A1298C). 7 Both are associated with a deficiency in enzymatic activity. 8 The MTHFR rs1801133 polymorphism is a point mutation at the position 677C>T, in which alanine is replaced with valine. 9 The MTHFR rs1801131 polymorphism is a point mutation at position 1298A>C, in which glutamate is replaced with valine. 10 The rs1801133 and rs1801131 polymorphisms reduce the activity of the MTHFR enzyme and increase the homocysteine level in the blood, which may be a risk factor for cancer. 11 Recently, some meta-analyses have reported significant correlations between the MTHFR rs1801133 and rs1801131 polymorphisms and tumour responses to chemoradiotherapy and short-term clinical benefits. [12] [13] [14] For example, two meta-analyses were performed to investigate the associations between MTHFR polymorphisms and the response of patients with CRC to chemotherapy. 13, 14 A meta-analysis was conducted to investigate the associations between MTHFR polymorphisms and short-term clinical benefits (complete or partial response, relapse or progression) of chemotherapy in patients with CRC. 12 These meta-analyses only focused on the short-term prognostic effects of MTHFR polymorphisms on patients with CRC.
No meta-analysis has been performed investigating the association between these MTHFR polymorphisms and survival (e.g. overall survival [OS], progression-free survival [PFS] or disease-free survival [DFS]). By systematically reviewing recent publications, we conducted a meta-analysis according to the guidelines of the PRISMA statement. 15 The aim was to explore whether the MTHFR rs1801133 and rs1801131 polymorphisms might affect the prognosis of patients with CRC and whether these SNPs are potentially useful as predictive biomarkers. Meier and Cox). The detailed search strategy is documented in the Supporting information (Doc. S1). Google Scholar was also used to search for relevant articles. Systematic reviews and meta-analyses of MTHFR polymorphisms and CRC were manually screened for potentially eligible articles.
| MATERIALS AND METHODS

| Literature search strategy
Duplicate articles that were obtained from multiple databases were deleted. The abstract of each article was extracted and screened by two of three investigators (FZ, TGY and GT), and the full texts of potentially eligible articles were reviewed for data analysis. Next, two of three investigators (FZ, TGY and GT) independently reviewed and confirmed the eligibility of the articles. Any disagreement was recorded and resolved by consensus under the guidance of a fourth investigator (XLC). The cross-referencing strategy was adopted until the two investigators reached a consistent result. or the relevant information (e.g. survival curves) were provided. Articles published in abstract form were included only when sufficient outcome data were presented or when the authors were willing to provide detailed results from the study. If several articles from the same patient population were reported, the most recent or most detailed study was included.
| Inclusion criteria for the studies
| Data extraction and quality assessment
For each article, two of three investigators (FZ, TGY and GT) independently extracted the required data according to a predefined protocol.
The extracted data comprised: authors' names, year of publication, patient characteristics (cancer type, sample size, gender and mean age), therapy (surgery, chemotherapy and radiotherapy), characteristics of MTHFR polymorphisms (rs1801133 or rs1801131, sample source, sample content, test method and cut-off values) and prognostic outcomes (HRs and their 95% CIs for OS, PFS and DFS). If the data from any of the above categories were unavailable in the text, the corresponding record was marked as "NR (not reported)". Differences in data extraction were resolved by cross-checking until a consensus was reached. inclusion criteria were excluded. The full texts of the remaining 73 articles were retrieved. Finally, twenty-four articles were included in the meta-analysis. 22 and the other studied colon cancer. 28 In total, 5423 patients with CRC were included in our analysis. The sample size of each article ranged from 29 to 784 patients, with a median of 136 patients. All patients received either 5-fluorouracil (5-FU) or 5-FU-based chemotherapy. Information about the rs1801133 and rs1801131 polymorphisms is provided in Table 2 .
| Statistical analysis
| RESULTS
| Article characteristics
| Meta-analysis of rs1801133
Twenty-three of the included articles assessed the association between rs1801133 and survival time. According to the heterogeneity analysis, all of the articles were homogeneous and the fixed-effect model was 
| Meta-analysis of rs1801131
Thirteen articles assessed the association between rs1801131 and survival time. Significant differences in OS, PFS and DFS were not observed between patients carrying the CC genotype and patients carrying the AA genotype ( (Figure 2 and Table 5 ). Significant differences in OS, PFS and DFS were not observed between patients with the CC + CA genotypes and patients with the AA genotype ( Table 5 ). Significant differences in OS, PFS and DFS were not observed between patients with the CA genotype and patients with the AA genotype (Table 5) .
Subgroup analysis revealed similar results for patients with CRC from Asian regions and Western regions ( Table 6 ). For example, the HR of the CC versus AA genotype in patients from Asian regions was 0.81 (95% CI = 0.51-1.29) and the HR for this same comparison of patients from Western regions was 1.25 (95% CI = 0.82-1.91).
| DISCUSSION
Our meta-analysis highlighted the long-term prognostic effects (including OS, PFS and DFS) of MTHFR polymorphisms on patients with CRC. The rs1801131 polymorphism may predict the prognosis.
Compared with patients with the CA + AA genotypes, patients with the CC genotype had a shorter OS (HR = 1.85) and DFS (HR = 2.15).
However, significant differences were not observed among the other comparisons (CC versus AA, CC + CA versus AA and CA versus AA).
Other researchers also reported similar results. For example, rs1801131 appears to be a potential prognostic factor for patients with gastric cancer. 13, 44, 45 The MTHFR rs1801131 polymorphism may predict the prognosis; the possible explanations are described below. As a crucial enzyme in metabolism, MTHFR catalyses the transformation of 5,10-MTHF into 5-MTHF. 25, [46] [47] [48] Notably, 5,10-MTHF mainly synthesizes purines and thymidine. Furthermore, 5-MTHF participates in the synthesis of S-adenosyl-methionine, which is an important mediator of methylation reactions. 47, 48 Regarding rs1801131, its mutation is linked to reduced MTHFR enzyme activity, although the decrease is less pronounced than the change induced by 677CNT. 49 Therefore, the reduction in enhance its growth and progression, 42, 48, 50, 51 presumably by providing large amounts of nucleotide precursors for tumour growth. 42, 48, 51 Folate supplementation is associated with a higher risk of CRC. 52 These findings indicate a negative effect of high levels of MTHFR on patients with CRC. Therefore, the association between MTHFR polymorphisms and a worse prognosis of CRC may be ascribed to decreased MTHFR activity.
In the present study, data heterogeneity was not observed; therefore, all of the data were analysed using fixed-effects models.
Subgroup analysis was performed according to the patient's nationality and revealed that rs1801133 and rs1801131 exerted the same effects on patients from Asian regions and patients from Western regions.
The MTHFR rs1801131 polymorphism may be associated with the prognosis of patients with CRC. In the future, additional high-quality prospective studies should be conducted to obtain a better understanding of the prognostic value of the MTHFR polymorphisms. The MTHFR rs1801131 polymorphism may be regarded as a target for drugs that are widely used to treat cancer and inflammatory diseases. 12 
